Upsher-Smith launches generic Aromasin
MAPLE GROVE, Minn. — Upsher-Smith Laboratories has introduced its generic of Aromasin (exemestane) tablets. The drug is an aromatase inhibitor indicated as an adjuvant treatment in postmenopausal women with breast cancer than has been treated with tamoxifen.
"We are pleased to offer physicians and patients a cost-effective alternative to Aromasin.” Upsher-Smith president and CEO Rusty Field said. "The addition of exemestane tablets supports our company's ongoing commitment to expanding our product portfolio and making quality, reasonably priced generics available to the most patients possible.”
The drug had U.S. sales of approximately $84 million for the 12 months ended August 31, according to QuintilesIMS data. It is available in 25-mg dosage strength.
Lupin acquires Symbiomix Therapeutics
MUMBAI, India — Lupin’s U.S. subsidiary’s latest acquisition is set to strengthen its pipeline for gynecologic drugs. The company has acquired Symbiomix Therapeutics for $150 million, which includes an upfront payment of $50 million and closed today.
With the acquisition, Lupin brings into its portfolio the Symbiomix’s Solosec franchise, expanding its women’s health specialty business, currently anchored by Lupin’s Methergine tablets. Solosec oral granules — a single-dose treatment for bacterial vaginosis — was approved by the Food and Drug Administration in mid-September and is set to be launched mid-2018. Having been designated by the FDA as a Qualified Infectious Disease Product, Solosec is eligible for 10 years of U.S. exclusivity, the company said.
“We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s U.S. women’s health specialty business into the highly-complementary gynecological infection sector,” Lupin CEO Vinita Gupta said. “This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”
Diplomat to dispense Verzenio
FLINT, Mich. — Diplomat Pharmacy has begun filling prescriptions for patients prescribed the recently approved breast cancer treatment Verzenio (abemaciclib). The drug was approved to treat certain cases of advanced or metastatic breast cancer, either alone or in combination with Faslodex.
"This therapy represents yet another step forward in the way the healthcare community approaches treating advanced stages of this disease,” Diplomat president Joel Saban said. “We are proud to support patients dealing with breast cancer by dispensing VERZENIO.”
The American Cancer Society projects that more than 250,000 breast cancer diagnoses will be made in 2017.